NCT04446416 2026-04-09
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
NaviFUS Corporation
Phase NA Completed
Clinical Trials
19 trialsNCT06329570 2026-04-09
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS Corporation
Phase 1/2 Recruiting
NCT06496971 2026-04-09
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NaviFUS Corporation
Phase 3 Recruiting
NCT01743950 2026-03-25
A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
University of Wisconsin, Madison
Phase 2 Terminated
NCT07297212 2026-03-12
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
Phase 2 Recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT02669173 2026-02-23
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Completed
NCT07263438 2026-02-13
Phenix
Centre Hospitalier Universitaire Vaudois
Phase 2 Recruiting
NCT06061809 2026-02-12
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
ImmunityBio, Inc.
Phase 2 Recruiting
NCT05871021 2026-01-09
PRIDE
University Hospital Tuebingen
Phase 2 Recruiting
NCT03743662 2026-01-07
Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05956821 2025-12-08
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
University of Miami
Phase 1/2 Recruiting
NCT03532295 2025-11-21
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Washington University School of Medicine
Phase 2 Completed
NCT02142803 2025-11-13
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04074785 2025-08-17
SCCC-06319
University of Texas Southwestern Medical Center
Phase EARLY_PHASE1 Terminated
NCT02974621 2025-08-03
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05284643 2025-08-01
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
University of Miami
Phase NA Recruiting
NCT04121455 2025-06-25
GLORIA
TME Pharma AG
Phase 1/2 Active not recruiting
NCT04406272 2025-06-10
VB-111 in Surgically Accessible Recurrent/Progressive GBM
Dana-Farber Cancer Institute
Phase 2 Terminated